Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effects of nilotinib on single-dose warfarin pharmacokinetics and pharmacodynamics: a randomized, single-blind, two-period crossover study in healthy subjects.

Clinical drug investigation - 1 Jan 2011

Yin Ophelia Q P, Gallagher Neil, Fischer Deirdre, Zhao Lily, Zhou Wei, Leroy Elisabeth, Golor Georg, Schran Horst

Abstract excerpt

BACKGROUND AND OBJECTIVE: Nilotinib (Tasigna®), a highly selective and potent BCR-ABL tyrosine kinase inhibitor, is approved for the treatment of chronic myeloid leukaemia in the chronic phase (CML-CP) and the accelerated phase (CML-AP) in patients resistant or intolerant to prior therapy, includ...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cross-Over Studies
Share to Cytochrome P-450 CYP2C9
Share to Drug Interactions

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fusion Proteins, bcr-abl

Share to International Normalized Ratio

Share to Prothrombin Time

Share to Single-Blind Method

Share to Warfarin

Source

Identifiers

PMID: 21184622
DOI: 10.2165/11538700-000000000-00000

Genes

BCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-21184622-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effects of nilotinib on single-dose warfarin pharmacokinetics and pharmacodynamics: a randomized, single-blind, two-period crossover study in healthy subjects.PMID 21184622Read ↗

Inter-individual differences in baseline coagulation activities and their implications for international normalized ratio control during warfarin initiation therapy.Semantic proximity Read ↗

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.Semantic proximity Read ↗

Limited sampling strategy of S-warfarin concentrations, but not warfarin S/R ratios, accurately predicts S-warfarin AUC during baseline and inhibition in CYP2C9 extensive metabolizers.Semantic proximity Read ↗

Effect of the CYP2C19 genotype on the pharmacokinetics of icotinib in healthy male volunteers.Semantic proximity Read ↗

Phase 1 study to investigate the pharmacokinetic properties of dacomitinib in healthy adult Chinese subjects genotyped for CYP2D6.Semantic proximity Read ↗

S-Warfarin Limited Sampling Models to Estimate Area Under the Concentration Versus Time Curve for Cytochrome P450 2C9 Baseline Activity and After Induction.Semantic proximity Read ↗

Effects of lasofoxifene on the pharmacokinetics and pharmacodynamics of single-dose warfarin.Semantic proximity Read ↗

UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia.Semantic proximity Read ↗

Lack of effect of Imrecoxib, an innovative and moderate COX-2 inhibitor, on pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers.Semantic proximity Read ↗

In Vivo Functional Effects of CYP2C9 M1L, a Novel and Common Variant in the Yup'ik Alaska Native Population.Semantic proximity Read ↗

Influence of UGT1A1 6, 27, and 28 polymorphisms on nilotinib-induced hyperbilirubinemia in Japanese patients with chronic myeloid leukemia.Semantic proximity Read ↗

Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.